T. Feys MBA, MSc

Novelties in the treatment of sickle cell disease

Summary

At the 2015 annual meeting of the American Society of Hemtology (ASH), potentially practice-changing novelties were published, which reform our way of thinking about sickle cell disease. Three highlighted studies were mentioned, two of these present promising new insights for managing the disease in children, the third demonstrates a new oral therapy.

(BELG J HEMATOL 2016; 7(1): 53–4)

Highlights in chronic myeloid leukemia and myeloproliferative neoplasms

Summary

Major therapeutic progress has been accomplished in chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPN) over the past 40 years. Therapeutic progress happened through better understanding of disease pathophysiologiy and rational development of targeted agents, like imatinib mesylate in CML. This report will discuss the key studies related to CML or MDS, presented during the 2015 annual ASH meeting of the American Society of Hematology (ASH).

(BELG J HEMATOL 2016; 7(1):9–13)

New haematology reimbursements in Belgium

Overview of Belgian reimbursement news

(Belg J Hematol 2015;6(5):225)

Blinatumomab: new hope for patients with relapsed/refractory acute lymphoblastic leukemia

(BELG J HEMATOL 2015;6(3):93–5)

Best of ASH

Summary

From the 8^th till the 11^th of December 2012, Atlanta, Georgia formed the background for the 54^th annual meeting of the American Society of Hematology (ASH). With more than 20,000 attendees from 108 countries, the ASH annual meeting again proved to be without question the premier hematology meeting in the world. This report does not aim to summarise the entire meeting, but simply lists the key messages from this years’ meeting. For more elaborate information on the meeting, and a complete overview of the presented abstracts we would like to refer to the ASH website, www.hematology.org.

(BELG J HEMATOL 2013;1:39–42)